Publication date: December 2019 Source: Neuropsychopharmacology, Volume 44, Issue 13 Author(s): Michael E. Thase, Arielle D. Stanford, Asli Memisoglu, William Martin, Amy Claxton, J. Alexander Bodkin, Madhukar H. Trivedi, Maurizio Fava, Miao Yu, Sanjeev Pathak
Results from a long-term open-label extension study of adjunctive buprenorphine/samidorphan combination in patients with major depressive disorder. // Neuropsychopharmacology. – URL: https://www.sciencedirect.com/science/article/pii/S0893133X26036596?dgcid=rss_sd_all
Results from a long-term open-label extension study of adjunctive buprenorphine/samidorphan combination in patients with major depressive disorder. Neuropsychopharmacology. https://www.sciencedirect.com/science/article/pii/S0893133X26036596?dgcid=rss_sd_all
“Results from a long-term open-label extension study of adjunctive buprenorphine/samidorphan combination in patients with major depressive disorder.” Neuropsychopharmacology.
@article{article60025,
title = {Results from a long-term open-label extension study of adjunctive buprenorphine/samidorphan combination in patients with major depressive disorder},
journal = {Neuropsychopharmacology},
url = {https://www.sciencedirect.com/science/article/pii/S0893133X26036596?dgcid=rss_sd_all}
}
Acta Pharmacologica Sinica, Published online: 16 November 2026; doi:10.1038/s41401-026-01953-z IRAK4 inhibitor DW18134 ameliorates diffuse large B-cell lymphoma in combination with ibrutinib and overcomes acquired resistance to ibrutinib
Acta Pharmacologica Sinica, Published online: 16 November 2026; doi:10.1038/s41401-026-01958-8 Artificial intelligence aids multi-omics data integration in cancer drug discovery and development: from targets to drug synergy
Nature Reviews Drug Discovery, Published online: 13 November 2026; doi:10.1038/d41573-026-00179-2 The NIH’s P. J. Brooks discusses the challenges and opportunities ahead for gene therapies and gene editing for diseases of no commercial interest.
Nature Reviews Drug Discovery, Published online: 13 November 2026; doi:10.1038/d41573-026-00181-8 Merck and Moderna’s intismeran autogene succeeded in a landmark melanoma trial, but the oncology community still has more questions than...